Israel state records י"ג בשבט התשס"ח January 20, 2008

גן וחלבון המקושרים להעדר חמצן	HYPOXIA-RELATED GENE AND POLYPEPTIDE
[54]
	21.08.1998					[22]
	US	[33]	21.08.1997	[32]	60/056453	[31]
Int. Cl.8 C07H 021/04, C07K 014/47, 016/18, C12N 015/12						[51]
			QUARK PHARMACEUTICALS, INC., U.S.A.			[71]
	WO/1999/009049					[87]
יהודית אברהמס, קיו.בי.אי. מפעלים בע"מ, , ת.ד. 4071, נס ציונה			JUDITH ABRAHAMS, P.O.B. 4071, NES ZIONA 70400			[74]

[57] An isolated polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:9 and SEQ ID NO:10.

__________

135102			[21][11]
חלבונים ממוזגים המכילים חלבוני – HIV–1 ו/או NEF			FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS			[54]
	17.09.1998					[22]
	GB	[33]	26.09.1997	[32]	9720585.0	[31]
Int. Cl.8 A61K 039/21, C07K 014/16, C12N 015/49, 015/62						[51]
			SMITHKLINE BEECHAM BIOLOGICALS S.A., BELGIUM			[71]
	WO/1999/016884					[87]
ריינהולד כהן ושותפיו, רחוב אחד העם 21 , ת.ד. 4060, תל אביב			REINHOLD COHN AND PARTNERS, 21 AHAD HA'AM ST., P.O.B. 4060, TEL AVIV 61040			[74]

[57] A vaccine composition which comprises a protein comprising:

(a) an entire HIV Tat protein or Tat with a C-terminal histidine tail, or a mutated Tat which has undergone deletion, addition or substitution of one amino acid, or a mutated Tat as defined by SEQ ID NO. 23, linked to either

(i) a protein or lipoprotein fusion partner or (ii) an entire HIV Nef protein or Nef with a C-terminal histidine tail, or Nef which has undergone deletion, addition or substitution of one amino acid; or

(b) an entire HIV Nef protein or Nef with a C-terminal histidine tail, or Nef which has undergone deletion, addition or substitution of one amino acid, linked to either (i) a protein or lipoprotein fusion partner or (ii) an entire HIV Tat protein or Tat with a C-terminal histidine tail, or a mutated Tat which has undergone deletion, addition or substitution of one amino acid, or a mutated Tat as defined by SEQ ID NO.23; or

(c) an entire HIV Nef protein or Nef with a C-terminal histidine tail, or Net which has undergone deletion, addition or substitution of one amino acid, linked to an entire HIV Tat protein or Tat with a C-terminal histidine tail, or a mutated Tat which as undergone deletion, addition or substitution of one amino acid, or a mutated Tat as defined by SEQ ID NO.23, and a protein or lipoprotein fusion partner, in admixture with a pharmaceutically acceptable excipient.

__________

135236			[21][11]
התקן אופטי			OPTICAL DEVICE			[54]
	08.10.1998					[22]
	FR	[33]	10.10.1997	[32]	97/12681	[31]
Int. Cl.8 G02B 027/01						[51]
			SEXTANT AVIONIQUE, FRANCE			[71]
	WO/1999/019757					[87]
ריינהולד כהן ושותפיו, רחוב אחד העם 21 , ת.ד. 4060, תל אביב			REINHOLD COHN AND PARTNERS, 21 AHAD HA'AM ST., P.O.B. 4060, TEL AVIV 61040			[74]

[57] Optical device for a system for the presentation of collimated images through the pupil of the eye (3) of a user comprising an imager (20), an off-axis concave mirror (1) and a Mangin mirror (21), the path of the ray passing through a centre of the pupil of the eye and the centre of the imager forming a broken-line optical axis (31, 32), wherein the said concave mirror is inclined with respect to a first part of the optical axis between the said centre of the pupil and the said concave mirror, and in that the said Mangin mirror is inclined on a second part of the optical axis corresponding to the reflection of the first part of the optical axis on the concave mirror and comprises a first reflecting surface (23) and a layer of refracting material (27), defining a second refracting surface, the said reflecting surface allowing the correction of the distortion of the image presented to the user and due to the off-axis concave mirror, and the optical thickness of the layer between the two surfaces being variable over the surface of the mirror in such a way as to compensate for the degradation in the resolution introduced by the said reflecting surface.

__________

135718			[21][11]